Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

StatusCompleted
PhasePhase 2
SponsorHutchmed
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 4 more changesShow less
    • Study completion date changed from estimate of Nov 12, 2026 to May 23, 2026
    • Eligibility criteria expanded, about 15 words
    • Secondary endpoints: details revised at 3 of 13 entries
    • Site details revised at 2 of 16 sites
  2. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 60 to confirmed 61
    • Study sites: 23 to 16
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 23
    • Start date changed from estimate of Oct 29, 2024 to Nov 5, 2024
    • Study title revised
    v2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Hutchmed
23 trials monitored
See 1 trial at risk
Non-Hodgkin Lymphoma
2,017 trials monitored
See 114 trials at risk
DLBCL
706 trials monitored
See 46 trials at risk
The goal of this study is to evaluate the efficacy of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL).
Trial Details
NCT Number NCT06601504
Lead Sponsor Hutchmed
Conditions
(from sponsor)		 Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Related terms Lymphoma, Large B-Cell, Diffuse
Enrollment 61 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov